X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs CIPLA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD CIPLA LUPIN LTD/
CIPLA
 
P/E (TTM) x 16.8 44.7 37.7% View Chart
P/BV x 3.9 3.7 106.4% View Chart
Dividend Yield % 0.8 0.3 225.3%  

Financials

 LUPIN LTD   CIPLA
EQUITY SHARE DATA
    LUPIN LTD
Mar-16
CIPLA
Mar-17
LUPIN LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,127622 342.0%   
Low Rs1,294458 282.4%   
Sales per share (Unadj.) Rs304.1181.9 167.2%  
Earnings per share (Unadj.) Rs50.412.9 391.6%  
Cash flow per share (Unadj.) Rs60.729.3 207.0%  
Dividends per share (Unadj.) Rs7.502.00 375.0%  
Dividend yield (eoy) %0.40.4 118.4%  
Book value per share (Unadj.) Rs243.8155.7 156.6%  
Shares outstanding (eoy) m450.58804.51 56.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.63.0 189.4%   
Avg P/E ratio x33.942.0 80.9%  
P/CF ratio (eoy) x28.218.4 153.0%  
Price / Book Value ratio x7.03.5 202.3%  
Dividend payout %14.915.5 95.8%   
Avg Mkt Cap Rs m770,740434,516 177.4%   
No. of employees `00016.423.0 71.0%   
Total wages/salary Rs m21,07726,338 80.0%   
Avg. sales/employee Rs Th8,379.66,349.1 132.0%   
Avg. wages/employee Rs Th1,289.01,143.0 112.8%   
Avg. net profit/employee Rs Th1,388.7449.3 309.1%   
INCOME DATA
Net Sales Rs m137,016146,302 93.7%  
Other income Rs m1,8772,287 82.1%   
Total revenues Rs m138,893148,589 93.5%   
Gross profit Rs m37,53524,758 151.6%  
Depreciation Rs m4,63513,229 35.0%   
Interest Rs m4461,594 28.0%   
Profit before tax Rs m34,33012,222 280.9%   
Minority Interest Rs m-880-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m11,5361,798 641.7%   
Profit after tax Rs m22,70710,354 219.3%  
Gross profit margin %27.416.9 161.9%  
Effective tax rate %33.614.7 228.5%   
Net profit margin %16.67.1 234.2%  
BALANCE SHEET DATA
Current assets Rs m97,79087,370 111.9%   
Current liabilities Rs m53,87233,081 162.9%   
Net working cap to sales %32.137.1 86.4%  
Current ratio x1.82.6 68.7%  
Inventory Days Days8587 97.4%  
Debtors Days Days12162 194.5%  
Net fixed assets Rs m86,379111,567 77.4%   
Share capital Rs m9011,609 56.0%   
"Free" reserves Rs m105,735123,645 85.5%   
Net worth Rs m109,844125,254 87.7%   
Long term debt Rs m53,73936,454 147.4%   
Total assets Rs m224,378209,532 107.1%  
Interest coverage x77.98.7 899.1%   
Debt to equity ratio x0.50.3 168.1%  
Sales to assets ratio x0.60.7 87.5%   
Return on assets %10.35.7 181.0%  
Return on equity %20.78.3 250.1%  
Return on capital %21.28.5 249.5%  
Exports to sales %49.134.2 143.5%   
Imports to sales %7.48.3 89.2%   
Exports (fob) Rs m67,24450,050 134.4%   
Imports (cif) Rs m10,19912,203 83.6%   
Fx inflow Rs m71,40551,066 139.8%   
Fx outflow Rs m17,80717,678 100.7%   
Net fx Rs m53,59833,388 160.5%   
CASH FLOW
From Operations Rs m-3,69023,824 -15.5%  
From Investments Rs m-69,434-13,127 529.0%  
From Financial Activity Rs m58,126-13,239 -439.1%  
Net Cashflow Rs m-14,998-2,478 605.2%  

Share Holding

Indian Promoters % 46.6 16.0 291.3%  
Foreign collaborators % 0.2 20.8 1.0%  
Indian inst/Mut Fund % 11.3 12.2 92.6%  
FIIs % 31.9 23.7 134.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.1 26.2 38.5%  
Shareholders   98,259 161,166 61.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  AUROBINDO PHARMA  

Compare LUPIN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 17, 2017 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS